185 related articles for article (PubMed ID: 35852473)
21. Plasma Epstein-Barr Virus MicroRNA BART8-3p as a Diagnostic and Prognostic Biomarker in Nasopharyngeal Carcinoma.
Lin C; Lin K; Zhang B; Su Y; Guo Q; Lu T; Xu Y; Lin S; Zong J; Pan J
Oncologist; 2022 Apr; 27(4):e340-e349. PubMed ID: 35380720
[TBL] [Abstract][Full Text] [Related]
22. Serologic antienzyme rate of Epstein-Barr virus DNase-specific neutralizing antibody segregates TNM classification in nasopharyngeal carcinoma.
Xu J; Wan XB; Huang XF; Chan KC; Hong MH; Wang LH; Long ZJ; Liu Q; Yan M; Lo YM; Zeng YX; Liu Q
J Clin Oncol; 2010 Dec; 28(35):5202-9. PubMed ID: 21060035
[TBL] [Abstract][Full Text] [Related]
23. Individualized induction chemotherapy by pre-treatment plasma Epstein-Barr viral DNA in advanced nasopharyngeal carcinoma.
Zhang J; Peng H; Li WF; Zhang Y; Liu LZ; Tian L; Lin AH; Sun Y; Ma J
BMC Cancer; 2018 Dec; 18(1):1276. PubMed ID: 30567511
[TBL] [Abstract][Full Text] [Related]
24. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in stage III-IVb nasopharyngeal carcinoma patients with Epstein-Barr virus DNA ≥4000 copies/ml: a matched study.
Guo SS; Tang LQ; Chen QY; Zhang L; Liu LT; Guo L; Mo HY; Luo DH; Huang PY; Xiang YQ; Sun R; Chen MY; Wang L; Lv X; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Hong MH; Shao JY; Sun Y; Ma J; Mai HQ
Oncotarget; 2016 May; 7(20):29739-48. PubMed ID: 27105538
[TBL] [Abstract][Full Text] [Related]
25. Can Epstein-Barr virus-deoxyribonucleic acid load after induction chemotherapy combined with American Joint Committee on Cancer stage determine the chemotherapy intensity of locally advanced nasopharyngeal carcinoma?
Zhang Q; Peng ZW; Gu ZS; Wang Y; He F; Zhao WB; Luo W; Mei YY
Cancer Med; 2023 Jan; 12(1):223-235. PubMed ID: 35674137
[TBL] [Abstract][Full Text] [Related]
26. The addition of pretreatment plasma Epstein-Barr virus DNA into the eighth edition of nasopharyngeal cancer TNM stage classification.
Lee VH; Kwong DL; Leung TW; Choi CW; O'Sullivan B; Lam KO; Lai V; Khong PL; Chan SK; Ng CY; Tong CC; Ho PP; Chan WL; Wong LS; Leung DK; Chan SY; So TH; Luk MY; Lee AW
Int J Cancer; 2019 Apr; 144(7):1713-1722. PubMed ID: 30192385
[TBL] [Abstract][Full Text] [Related]
27. Comparing three induction chemotherapy regimens for patients with locoregionally advanced nasopharyngeal carcinoma based on TNM stage and plasma Epstein-Barr virus DNA level.
Liu SL; Sun XS; Xie HJ; Chen QY; Lin HX; Liang H; Liang YJ; Li XY; Yan JJ; Lin C; Yang ZC; Guo SS; Liu LT; Tang QN; Du YY; Tang LQ; Guo L; Mai HQ
BMC Cancer; 2020 Feb; 20(1):89. PubMed ID: 32013967
[TBL] [Abstract][Full Text] [Related]
28. Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma.
Guo R; Tang LL; Mao YP; Du XJ; Chen L; Zhang ZC; Liu LZ; Tian L; Luo XT; Xie YB; Ren J; Sun Y; Ma J
Cancer; 2019 Jan; 125(1):79-89. PubMed ID: 30351466
[TBL] [Abstract][Full Text] [Related]
29. The diagnostic and prognostic values of plasma Epstein-Barr virus DNA for residual cervical lymphadenopathy in nasopharyngeal carcinoma patients: a retrospective study.
Liu SL; Sun XS; Li XY; Tang LQ; Chen QY; Lin HX; Liang YJ; Yan JJ; Lin C; Guo SS; Liu LT; Li Y; Xie HJ; Tang QN; Liang H; Guo L; Mai HQ
Cancer Commun (Lond); 2019 Mar; 39(1):14. PubMed ID: 30925939
[TBL] [Abstract][Full Text] [Related]
30. Plasma Epstein-Barr Viral Deoxyribonucleic Acid Predicts Worse Outcomes in Pediatric Nonmetastatic Nasopharyngeal Carcinoma Patients: An Observational Study of 89 Cases in an Endemic Area.
Shen T; Tang LQ; Gu WG; Luo DH; Chen QY; Li PJ; Mai DM; Mai HQ; Mo HY
Medicine (Baltimore); 2015 Dec; 94(50):e1945. PubMed ID: 26683909
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of serum uric acid and tumor response to induction chemotherapy in locally advanced nasopharyngeal carcinoma.
Xu Y; Wu Z; Ye W; Xiao Y; Zheng W; Chen Q; Bai P; Lin Z; Chen C
BMC Cancer; 2021 May; 21(1):519. PubMed ID: 33962583
[TBL] [Abstract][Full Text] [Related]
32. Circulating Plasma Epstein-Barr Virus DNA Load During the Follow-up Periods Predicts Recurrence and Metastasis in Nasopharyngeal Carcinoma.
He SS; Wang Y; Yang YY; Niu SQ; Zhu MY; Lu LX; Chen Y
Cancer J; 2022 Mar-Apr 01; 28(2):85-92. PubMed ID: 35333490
[TBL] [Abstract][Full Text] [Related]
33. Long-term monitoring of dynamic changes in plasma EBV DNA for improved prognosis prediction of nasopharyngeal carcinoma.
Li W; Chen J; Liang B; Li Z; Li J; Yuan X; Wu S; Zeng F; Peng X; Li Y; Lu J; Zhao F; Liu X
Cancer Med; 2021 Feb; 10(3):883-894. PubMed ID: 33378109
[TBL] [Abstract][Full Text] [Related]
34. Neoadjuvant or Adjuvant Chemotherapy Plus Concurrent CRT Versus Concurrent CRT Alone in the Treatment of Nasopharyngeal Carcinoma: A Study Based on EBV DNA.
Liu LT; Chen QY; Tang LQ; Guo SS; Guo L; Mo HY; Li Y; Tang QN; Sun XS; Liang YJ; Zhao C; Guo X; Qian CN; Zeng MS; Bei JX; Hong MH; Shao JY; Sun Y; Ma J; Mai HQ
J Natl Compr Canc Netw; 2019 Jun; 17(6):703-710. PubMed ID: 31200353
[TBL] [Abstract][Full Text] [Related]
35. Nomogram incorporating Epstein-Barr virus DNA and a novel immune-nutritional marker for survival prediction in nasopharyngeal carcinoma.
Wu S; Yuan X; Huang H; Li Y; Cui L; Lin D; Lu W; Feng H; Chen Z; Liu X; Tan J; Wang F
BMC Cancer; 2023 Dec; 23(1):1217. PubMed ID: 38066499
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of gross tumor regression and plasma Epstein Barr Virus DNA levels at the end of intensity-modulated radiation therapy in patients with nasopharyngeal carcinoma.
Liang SB; Zhang N; Chen DM; Yang XL; Chen BH; Zhao H; Lu RL; Chen Y; Fu LW
Radiother Oncol; 2019 Mar; 132():223-229. PubMed ID: 30366725
[TBL] [Abstract][Full Text] [Related]
37. Circulating Epstein-Barr virus microRNAs BART7-3p and BART13-3p as novel biomarkers in nasopharyngeal carcinoma.
Lu T; Guo Q; Lin K; Chen H; Chen Y; Xu Y; Lin C; Su Y; Chen Y; Chen M; Zheng Y; Ye Y; Lin S; Zong J; Pan J
Cancer Sci; 2020 May; 111(5):1711-1723. PubMed ID: 32155300
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of Epstein-Barr virus DNA load in nasopharyngeal carcinoma: a meta-analysis.
Alami IE; Gihbid A; Charoute H; Khaali W; Brahim SM; Tawfiq N; Cadi R; Belghmi K; El Mzibri M; Khyatti M
Pan Afr Med J; 2022; 41():6. PubMed ID: 35145598
[TBL] [Abstract][Full Text] [Related]
39. Assessment of Survival Model Performance Following Inclusion of Epstein-Barr Virus DNA Status in Conventional TNM Staging Groups in Epstein-Barr Virus-Related Nasopharyngeal Carcinoma.
Li WZ; Wu HJ; Lv SH; Hu XF; Liang H; Liu GY; Lu N; Bei WX; Lv X; Guo X; Xia WX; Xiang YQ
JAMA Netw Open; 2021 Sep; 4(9):e2124721. PubMed ID: 34554238
[TBL] [Abstract][Full Text] [Related]
40. Combining plasma Epstein-Barr virus DNA and nodal maximal standard uptake values of 18F-fluoro-2-deoxy-D-glucose positron emission tomography improved prognostic stratification to predict distant metastasis for locoregionally advanced nasopharyngeal carcinoma.
Chen WH; Tang LQ; Zhang L; Chen QY; Guo SS; Liu LT; Fan W; Zhang X; Guo L; Zhao C; Cao KJ; Qian CN; Guo X; Xie D; Zeng MS; Mai HQ
Oncotarget; 2015 Nov; 6(35):38296-307. PubMed ID: 26512922
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
